ArriVent BioPharma, Inc. AVBP Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$43.32M-21.9% | -$35.54M-1.6% | -$34.98M-11.4% | -$31.4M+51.2% | -$64.39M-212% | ||
| -$559K+26.1% | -$756.5K0.0% | -$756.5K0.0% | -$756.5K0.0% | -$756.5K— | ||
| $5.49M+70.2% | $3.22M-13.3% | $3.72M+12.2% | $3.31M+45.8% | $2.27M+139% | ||
| -$41.89M-36.6% | -$30.66M+14.4% | -$35.8M-37.0% | -$26.12M+61.6% | -$68.01M-321% | ||
| $3.58M+105% | -$71.2M-40.3% | -$50.76M-465% | $13.91M-62.2% | $36.82M+177% | ||
| $54.87M+58.0% | $34.73M-59.8% | $86.47M+15.1% | $75.11M+1,011% | $6.76M+12,189% | ||
| $16.56M+125% | -$67.13M-72,085% | -$93K-100% | $62.9M+357% | -$24.43M+88.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does ArriVent BioPharma, Inc.'s cash flow data come from?
- Every line is extracted from ArriVent BioPharma, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.